Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood–brain barrier opening: A novel combinatorial immunotherapy regimen for gliomas is a research paper published in Neuro-Oncology (2024). On theSindex it has a DataRank of 0.706. It has been cited 34 times, with 29 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.533
From this paper's citation signal
Citation Network Contribution
0.172
From 19 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 29 citers.
NIH
Grant: 1R01CA245969-01A1
Blood-brain barrier disruption with implantable ultrasound to enhance paclitaxel delivery: A Phase 1-2 clinical trial in recurrent glioblastoma
NIH
Grant: 1U19CA264338-01
Advancing treatment and understanding of immunotherapy in glioblastoma
NIH
Grant: P50CA221747
SPORE
Grant: P50CA097257
SPORE
Grant: R01 CA120813
SPORE
Grant: RO1 NS120547
Panattoni family
Grant: R35CA253126
NCI NIH HHS
Grant: U19 CA264338
NCI NIH HHS
Grant: R01 CA245969
NINDS NIH HHS
Grant: R01 NS110703
NINDS NIH HHS
Grant: R01 NS120547
Moceri Family Foundation
Vagelos Precision Medicine
FWCI
9.30
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals